Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VRTX
DateTimeSourceHeadlineSymbolCompany
23/12/202421:05Business WireVertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13NASDAQ:VRTXVertex Pharmaceuticals Inc
20/12/202420:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
20/12/202420:46Business WireVertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
20/12/202420:35Business WireVertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive VariantsNASDAQ:VRTXVertex Pharmaceuticals Inc
19/12/202411:00Business WireVertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral RadiculopathyNASDAQ:VRTXVertex Pharmaceuticals Inc
08/12/202417:52Business WireVertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program UpdateNASDAQ:VRTXVertex Pharmaceuticals Inc
19/11/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
15/11/202415:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
13/11/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
12/11/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
08/11/202419:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
05/11/202421:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
05/11/202411:43IH Market NewsBoeing Ends Strike; Leadership Changes at Dollar Tree and Southwest; PLTR, HIMS, and ALAB Soar; MQ and LSCC DeclineNASDAQ:VRTXVertex Pharmaceuticals Inc
04/11/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
04/11/202421:01Business WireVertex Reports Third Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
29/10/202420:05Business WireVertex to Participate in Upcoming November Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
25/10/202417:00Business WireVertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week CongressNASDAQ:VRTXVertex Pharmaceuticals Inc
18/10/202412:00Business WireVertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual MeetingNASDAQ:VRTXVertex Pharmaceuticals Inc
17/10/202420:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
10/10/202420:05Business WireVertex to Announce Third Quarter 2024 Financial Results on November 4thNASDAQ:VRTXVertex Pharmaceuticals Inc
03/10/202420:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
02/10/202414:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
26/09/202413:00PR Newswire (Canada)Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
26/09/202413:00PR Newswire (Canada)Vertex annonce l'acceptation par Santé Canada de la soumission de drogue nouvelle pour l'association vanzacaftor/tézacaftor/deutivacaftor, un traitement d'association triple de nouvelle génération pour la fibrose kystiqueNASDAQ:VRTXVertex Pharmaceuticals Inc
26/09/202411:07Business WireVertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ConferenceNASDAQ:VRTXVertex Pharmaceuticals Inc
25/09/202419:51PR Newswire (Canada)Santé Canada accorde l'autorisation de mise sur le marché de la première thérapie d'édition génomique CRISPR/Cas9, CASGEVY® (exagamglogène autotemcel), pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusiNASDAQ:VRTXVertex Pharmaceuticals Inc
25/09/202419:50PR Newswire (Canada)Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
04/09/202420:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
04/09/202420:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
30/08/202420:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VRTX